Medicxi Ventures Management (Jersey) Ltd

CIK 0001715579 · ST. HELIER, Y9 · Quarter end: 2026-06-30 · Filed on: 2026-08-04 · Open the SEC source ↗

Medicxi Ventures Management (Jersey) Ltd reported 3 positions worth $177.4M as of June 30, 2026 (13F filed August 4, 2026). Largest holding: PHAT (45.6%).

Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.

$177.4M

2026 Q2

Positions

Top-10 ConcentrationHow much of the portfolio sits in the 10 largest holdings. High = concentrated bets.

100.0%

Est. Net Flow (Q)

—

2026 Q2

Positions Changes Mix History BacktestPRO

3 positions shown

#	Symbol	Company	Type	Value ↓	% Port.	Shares	1Y	YTD
▸ 1	PHAT	PHATHOM PHARMACEUTICALS INC	SH	$81.0M	45.65%	7,464,572	—	—
▸ 2	NAMS	NEWAMSTERDAM PHARMA COMPANY	SH	$74.9M	42.19%	2,208,639	—	—
▸ 3	AURA	AURA BIOSCIENCES INC	SH	$21.6M	12.16%	3,039,892	—	—

Read the 2026-Q2 quarterly report · 13F Filing Calendar

Frequently Asked Questions

What stocks does Medicxi Ventures Management (Jersey) Ltd hold as of Q2 2026?

Medicxi Ventures Management (Jersey) Ltd reported 3 positions worth $177.4M in its Q2 2026 13F filing. Largest positions: PHAT (45.6%), NAMS (42.2%) and AURA (12.2%).

What did Medicxi Ventures Management (Jersey) Ltd buy in Q2 2026?

No previous quarter is available yet; the comparison appears with the next filing.

What did Medicxi Ventures Management (Jersey) Ltd sell in Q2 2026?

No previous quarter is available yet.

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.